The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The Food and Drug Administration (FDA) has approved DefenCath ® (taurolidine and heparin) catheter lock solution to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
CorMedix’s CRMD lead drug, DefenCath (Taurolidine + Heparin), is currently its only marketed product that generates revenues for the company. The FDA approved CorMedix’s DefenCath in late 2023 as the ...
BERKELEY HEIGHTS, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (CRMD) (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for ...
The majority of CorMedix’s CRMD revenues come from its lead product, DefenCath, which is approved as the first and only antimicrobial catheter lock solution in the United States. The product is ...
Hosted on MSN
CorMedix Lifts Q2 Outlook As Dialysis Partner Expands DefenCath Use; Needham Raises PT To $20
CorMedix raised its second-quarter sales forecast on Monday after disclosing that its large dialysis organization (LDO) partner has started implementing DefenCath with a broader reach than previously ...
DefenCath is intended for instillation into central venous catheters only. DefenCath ® (taurolidine and heparin) catheter lock solution is now available for inpatient use to reduce the incidence of ...
BERKELEY HEIGHTS, N.J., Jan. 21, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results